Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 95
1.
J Hosp Infect ; 131: 234-243, 2023 Jan.
Article En | MEDLINE | ID: mdl-36414164

BACKGROUND: The increasing prevalence of multidrug-resistant organism (MDRO) carriage poses major challenges to medicine as healthcare costs increase. Recently, faecal microbiota transplantation (FMT) has been discussed as a novel and effective method for decolonizing MDRO. AIM: To compare the efficacy of different FMT methods to optimize the success rate of decolonization in patients with MDRO carriage. METHODS: This prospective cohort study enrolled patients with MDRO carriages from 2018 to 2021. Patients underwent FMT via one of the following methods: oral capsule, oesophagogastroduodenoscopy (EGD), colonoscopy, or gastric tube. FINDINGS: A total of 57 patients underwent FMT for MDRO decolonization. The colonoscopy group required the shortest time for decolonization, whereas the EGD group required the longest (24.9 vs 190.4 days, P = 0.022). The decolonization rate in the oral capsule group was comparable to that in the EGD group (84.6% vs 85.7%, P = 0.730). An important clinical factor associated with decolonization failure was antibiotic use after FMT (odds ratio = 6.810, P = 0.008). All four groups showed reduced proportions of MDRO species in microbiome analysis after FMT. CONCLUSION: Compared to other conventional methods, the oral capsule is an effective FMT method for patients who can tolerate an oral diet. The discontinuation of antibiotics after FMT is a key factor in the success of decolonization.


Anti-Bacterial Agents , Fecal Microbiota Transplantation , Humans , Fecal Microbiota Transplantation/methods , Feces , Prospective Studies , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Colonoscopy , Endoscopy, Digestive System , Treatment Outcome
3.
Br J Surg ; 108(11): 1332-1340, 2021 11 11.
Article En | MEDLINE | ID: mdl-34476473

BACKGROUND: Trials typically group cancers of the gastro-oesophageal junction (GOJ) with oesophageal or gastric cancer when studying neoadjuvant chemoradiation and perioperative chemotherapy, so the results may not be fully applicable to GOJ cancer. Because optimal neoadjuvant treatment for GOJ cancer remains controversial, outcomes with neoadjuvant chemoradiation versus chemotherapy for locally advanced GOJ adenocarcinoma were compared retrospectively. METHODS: Data were collected from all patients who underwent neoadjuvant treatment followed by surgery for adenocarcinoma located at the GOJ at a single high-volume institution between 2002 and 2017. Postoperative major complications and mortality were compared between groups using Fisher's exact test. Overall survival (OS) and disease-free survival (DFS) were assessed by log rank test and multivariable Cox regression analyses. Cumulative incidence functions were used to estimate recurrence, and groups were compared using Gray's test. RESULTS: Of 775 patients, 650 had neoadjuvant chemoradiation and 125 had chemotherapy. These groups were comparable in terms of clinical tumour and lymph node categories, although the chemoradiation group had greater proportions of white men, complete pathological response to chemotherapy, and smaller proportions of diffuse cancer, poor differentiation, and neurovascular invasion. Postoperative major complications (20.0 versus 17.6 per cent) and 30-day mortality (1.7 versus 1.6 per cent) were not significantly different between the chemoradiation and chemotherapy groups. After adjustment, type of therapy (chemoradiation versus chemotherapy) was not significantly associated with OS (hazard ratio (HR) 1.26, 95 per cent c.i. 0.96 to 1.67) or DFS (HR 1.27, 0.98 to 1.64). Type of recurrence (local, regional, or distant) did not differ after neoadjuvant chemoradiation versus chemotherapy. CONCLUSION: In patients undergoing surgical resection for locally advanced adenocarcinoma of the GOJ, OS and DFS did not differ significantly between patients who had neoadjuvant chemoradiation compared with chemotherapy.


Treating advanced cancer of the gastro-oesophageal junction (GOJ) poses a challenge given its location in the distal oesophagus and proximal stomach, and whether it should be treated as oesophageal or gastric cancer. Given the indistinct location, it is unclear whether GOJ cancer should be treated with neoadjuvant chemoradiation, which is the treatment of choice for advanced oesophageal cancers, or perioperative chemotherapy, which is the treatment of choice for advanced gastric cancers. Few studies have addressed treatment options specifically for GOJ cancers. This study investigated whether there was a difference in survival between patients with GOJ cancer who were treated with chemoradiation versus chemotherapy.


Adenocarcinoma/therapy , Antineoplastic Agents/therapeutic use , Esophageal Neoplasms/therapy , Esophagectomy/adverse effects , Esophagogastric Junction , Neoplasm Staging , Adenocarcinoma/diagnosis , Adenocarcinoma/mortality , Aged , Chemoradiotherapy, Adjuvant , Esophageal Neoplasms/diagnosis , Esophageal Neoplasms/mortality , Female , Follow-Up Studies , Humans , Incidence , Male , Middle Aged , New York/epidemiology , Postoperative Complications/epidemiology , Prognosis , Retrospective Studies , Survival Rate/trends
4.
Clin Microbiol Infect ; 27(1): 69-75, 2021 Jan.
Article En | MEDLINE | ID: mdl-32272171

OBJECTIVES: Recently, rapid phenotypic antimicrobial susceptibility testing (AST) based on microscopic imaging analysis has been developed. The aim of this study was to determine whether implementation of antimicrobial stewardship programmes (ASP) based on rapid phenotypic AST can increase the proportion of patients with haematological malignancies who receive optimal targeted antibiotics during early periods of bacteraemia. METHODS: This randomized controlled trial enrolled patients with haematological malignancies and at least one positive blood culture. Patients were randomly assigned 1:1 to conventional (n = 60) or rapid phenotypic (n = 56) AST. The primary outcome was the proportion of patients receiving optimal targeted antibiotics 72 hr after blood collection for culture. RESULTS: The percentage receiving optimal targeted antibiotics at 72 hr was significantly higher in the rapid phenotypic AST group (45/56, 80.4%) than in conventional AST group (34/60, 56.7%) (relative risk (RR) 1.42, 95% confidence interval (CI) 1.09-1.83). The percentage receiving unnecessary broad-spectrum antibiotics at 72 hr was significantly lower (7/26, 12.5% vs 18/60, 30.0%; RR 0.42, 95% CI 0.19-0.92) and the mean time to optimal targeted antibiotic treatment was significantly shorter (38.1, standard deviation (SD) 38.2 vs 72.8, SD 93.0 hr; p < 0.001) in the rapid phenotypic AST group. The mean time from blood collection to the AST result was significantly shorter in the rapid phenotypic AST group (48.3, SD 17.6 vs 83.1, SD 22.2 hr). DISCUSSION: ASP based on rapid phenotypic AST can rapidly optimize antibiotic treatment for bacteraemia in patients with haematological malignancy. Rapid phenotypic AST can improve antimicrobial stewardship in immunocompromised patients.


Anti-Bacterial Agents/therapeutic use , Antimicrobial Stewardship/methods , Bacteremia/drug therapy , Hematologic Neoplasms/drug therapy , Microbial Sensitivity Tests/methods , Adult , Anti-Bacterial Agents/pharmacology , Bacteremia/complications , Female , Hematologic Neoplasms/complications , Humans , Male , Middle Aged , Time-to-Treatment , Treatment Outcome
7.
Fam Cancer ; 18(4): 429-438, 2019 10.
Article En | MEDLINE | ID: mdl-31273560

Germline CDH1 mutation carriers are at risk for early-onset diffuse gastric cancer (DGC) and female carriers have an additional risk of lobular breast cancer. The reported literature GC risk of 70% has led to the recommendation for germline mutation carriers to undergo prophylactic total gastrectomy (PTG). The objective of this research was to examine post-surgical clinical outcomes and to identify which of the domains/symptoms from the European Organisation for Research and Treatment of Cancer QOL Questionnaire (EORTC QLQ-C30) were determinants of overall quality of life (QOL) in individuals undergoing PTG. Participants were recruited through multiple sources. Postsurgical clinical outcomes were obtained from hospital records. Participants completed validated questionnaires measuring generic and condition specific QOL (PROMIS, EORTC and SF 36v.II) at a single point in time. The mean QOL in this cohort was 70.6 (SD = 25.6), which is better than reference values from the general populations in USA and Canada Role and social function plus the symptoms anxiety, pain, taste, dyspnea and diarrhea were significant predictor variables for QOL (p < 0.05). Although this study reveals good overall QOL for individuals after PTG, attention should be given to managing symptoms as part of long term care to further enhance QOL. The function/symptom scores were associated with worse overall health and global health status and thus may mark a real need for more attentive post-surgical care.


Gastrectomy/psychology , Postoperative Complications/etiology , Prophylactic Surgical Procedures/psychology , Stomach Neoplasms/prevention & control , Anxiety/etiology , Body Weight , Depression/etiology , Female , Gastrectomy/adverse effects , Humans , Laparoscopy/adverse effects , Laparoscopy/methods , Laparoscopy/psychology , Length of Stay , Male , Middle Aged , Patient Satisfaction , Prophylactic Surgical Procedures/adverse effects , Quality of Life , Retrospective Studies , Treatment Outcome
8.
Br J Surg ; 106(9): 1187-1196, 2019 08.
Article En | MEDLINE | ID: mdl-31197829

BACKGROUND: Neoadjuvant chemotherapy followed by gastrectomy with D2 lymphadenectomy is commonly used for patients with locally advanced gastric adenocarcinoma. The eighth AJCC ypTNM staging system was validated based on patients undergoing more limited lymphadenectomy (less than D2). The aim of this study was to develop a system for accurate staging of patients with locally advanced gastric adenocarcinoma who receive neoadjuvant chemotherapy followed by gastrectomy with D2 lymphadenectomy. METHODS: A modified system of ypTNM was developed, based on overall survival (OS) of patients receiving neoadjuvant chemotherapy followed by gastrectomy with D2 lymphadenectomy at Memorial Sloan Kettering Cancer Center, and validated using data from an international cohort of patients who had similar treatment. RESULTS: Of 325 patients in the derivation cohort, 33 (10·2 per cent) had ypT0 N0/+ tumours, which are not classifiable under the AJCC system. The 5-year OS rate for modified ypTNM stages I, II, IIIA and IIIB was 89, 71, 42·3 and 10 per cent respectively, compared with 82, 65·2 and 24·1 for AJCC stages I, II and III respectively. The concordance index (0·730 versus 0·709), estimated area under the curve (0·765 versus 0·740) and time-dependent receiver operating characteristic (ROC) curve throughout the observation period were all superior for modified ypTNM staging. For the validation cohort of 186 patients, the modified system was again better at separating patients into prognostic groups for OS. CONCLUSION: The modified ypTNM staging system improves the accuracy of OS prediction for patients treated with neoadjuvant chemotherapy followed by gastrectomy with D2 lymphadenectomy.


Adenocarcinoma/pathology , Antineoplastic Agents/therapeutic use , Gastrectomy , Lymph Node Excision , Neoadjuvant Therapy , Neoplasm Staging/methods , Stomach Neoplasms/pathology , Adenocarcinoma/diagnosis , Adenocarcinoma/mortality , Adenocarcinoma/therapy , Antineoplastic Agents/administration & dosage , Combined Modality Therapy , Female , Gastrectomy/methods , Humans , Kaplan-Meier Estimate , Lymph Node Excision/methods , Male , Middle Aged , Reproducibility of Results , Stomach Neoplasms/diagnosis , Stomach Neoplasms/mortality , Stomach Neoplasms/therapy , Survival Analysis
9.
Transplant Proc ; 50(10): 3088-3094, 2018 Dec.
Article En | MEDLINE | ID: mdl-30577171

BACKGROUND: The management of a deceased donor in the intensive care unit before organ transplantation is important for the outcome of the recipient. Herein, we analyze the pre-transplant resuscitation factors managed before procurement that could influence graft function immediately after deceased-donor kidney transplantation (DDKT). METHODS: A total of 271 DDKTs performed at Seoul St. Mary's Hospital, Korea, from January 2009 to March 2016 were reviewed. We divided the patients into a delayed graft function (DGF) group and a non-DGF group, and compared postoperative outcomes between the 2 groups. We also analyzed the predisposing factors of DGF using multivariate analysis. RESULTS: A total of 36 cases developed DGF while 235 patients did not, and the demographic characteristics of the recipients in the two groups had no significant difference. Of the pre-transplant resuscitation factors, preoperative polyuria, the maximal levels of serum sodium and BUN, and transfer times were significantly higher in the DGF group (P < .001). In a multivariable analysis, preoperative polyuria (odds ratio 4.835, P = .036), elevated preoperative level of sodium (odds ratio 1.227, P = .001), and extended transfer times (odds ratio 1.001, P < .001) were the independent risk factors of the donor in pre-transplant resuscitation management associated with DGF. CONCLUSIONS: Polyuria, high levels of sodium before procurement, and prolonged transfer times are independent risk factors for DGF after a DDKT. Active intervention and early implementation of the intensivist can help in managing these factors effectively and thus ultimately improve graft function.


Delayed Graft Function/etiology , Kidney Transplantation/methods , Tissue and Organ Procurement/methods , Transplants/physiopathology , Adult , Aged , Brain Death/physiopathology , Female , Humans , Kidney/physiopathology , Kidney Transplantation/adverse effects , Male , Middle Aged , Multivariate Analysis , Odds Ratio , Republic of Korea , Resuscitation/methods , Risk Factors , Tissue Donors , Treatment Outcome , Young Adult
10.
Bone Marrow Transplant ; 53(2): 207-212, 2018 02.
Article En | MEDLINE | ID: mdl-29084202

In vivo T-cell depletion using anti-thymocyte globulin (ATG) is widely used in allogeneic hematopoietic stem cell transplantation (HSCT) for prophylaxis of GvHD. We investigated the influence of thymoglobulin dose (an ATG) on GvHD following matched sibling donor (MSD) HSCT with a busulfan and fludarabine preparative regimen. Medical records of 180 patients who received MSD HSCT with a conditioning regimen of busulfan, fludarabine, and ATG (BuFluATG) were reviewed retrospectively. The median age was 53 years (range 18-68). Initial diagnoses were acute myeloid leukemia (73.3%) and myelodysplastic syndrome (26.7%). Forty-four and 68 patients (24.4 and 37.7%) experienced acute and chronic GvHD of any grade, respectively. High-dose (⩾4.5 mg/kg) ATG was independently associated with decreased risk of acute GvHD (hazard ratio=0.36, 95% confidence interval (CI): 0.15-0.84, P=0.019) compared to low-dose ATG (<4.5 mg/kg). Although ATG dose was associated with the risk of acute GvHD, it was not associated with the risk of chronic GvHD in our study. A higher dose (⩾4.5 mg/kg) of ATG decreases the risk of acute GvHD but had no significant impact on disease-free survival in MSD HSCT patients conditioned with BuFluATG. The optimal dose of ATG should be further investigated in a large prospective study context.


Antilymphocyte Serum/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Busulfan/therapeutic use , Hematopoietic Stem Cell Transplantation/methods , Immunosuppressive Agents/therapeutic use , Transplantation Conditioning/methods , Transplantation, Homologous/methods , Vidarabine/analogs & derivatives , Adolescent , Adult , Aged , Antilymphocyte Serum/pharmacology , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Busulfan/pharmacology , Female , Humans , Immunosuppressive Agents/pharmacology , Male , Middle Aged , Retrospective Studies , Vidarabine/pharmacology , Vidarabine/therapeutic use , Young Adult
12.
Mucosal Immunol ; 10(3): 757-774, 2017 05.
Article En | MEDLINE | ID: mdl-27554297

Nod-like receptor family, CARD domain-containing 4 (NLRC4) inflammasome activation is required for efficient clearance of intracellular pathogens through caspsase-1-dependent pyroptosis in macrophages. Although neutrophils have a critical role in protection from Pseudomonas aeruginosa infection, the mechanisms regulating inflammasome-mediated pyroptosis in neutrophils and its physiological role are largely unknown. We sought to determine the specific mechanisms regulating neutrophil pyroptosis in P. aeruginosa strain PAO1 (PAO1) lung infection and to identify the pathological role of this process. Nox2-/- models with reduced neutrophil antibacterial activity exhibited increased neutrophil pyroptosis, which was mediated by flagellin, a pathogenic PAO1 component. We also demonstrate that PAO1-induced pyroptosis depended on NLRC4 and Toll-like receptor 5 (TLR5) in neutrophils generated from Nlrc4-/- or Tlr5-/- mice. Our study reveals previously unknown mechanisms and physiological role of neutrophil pyroptosis during P. aeruginosa lung infection. Furthermore, our findings regarding neutrophil pyroptosis in the context of neutrophil dysfunction may explain the causes of acute and/or chronic infectious diseases discovered in immune-compromised patients.


Apoptosis , Inflammasomes/metabolism , Lung/immunology , NADPH Oxidase 2/metabolism , Neutrophils/immunology , Pseudomonas Infections/immunology , Pseudomonas aeruginosa/immunology , Animals , Apoptosis Regulatory Proteins/genetics , Calcium-Binding Proteins/genetics , Flagellin/metabolism , Humans , Immunocompromised Host , Lung/microbiology , Mice , Mice, Inbred C57BL , Mice, Knockout , NADPH Oxidase 2/genetics , NLR Family, Pyrin Domain-Containing 3 Protein/genetics , Neutrophils/microbiology , Toll-Like Receptor 5/genetics
14.
J Nanosci Nanotechnol ; 16(3): 2912-5, 2016 Mar.
Article En | MEDLINE | ID: mdl-27455733

We have synthesized four pyrene-derived blue emitting materials using Suzuki cross coupling reactions. All OLED devices using these materials as emitting materials showed efficient blue electroluminescence (EL). Particularly, a device using 1,1'-(9,9-dimethyl-9H-fluorene-2,7-diyl)bis-pyrene (1) showed best EL properties with the luminous efficiency of 4.32 cd/A, the power efficiency of 3.98 lm/W and the external quantum efficiency of 2.48% at 500 cd/m2.


Pyrenes/chemistry , Electrochemistry , Light , Spectrophotometry, Ultraviolet
15.
Trop Med Int Health ; 20(12): 1685-95, 2015 Dec.
Article En | MEDLINE | ID: mdl-26338026

OBJECTIVE: Universal coverage with insecticide-treated bed nets is a cornerstone of modern malaria control. Mozambique has developed a novel bed net allocation strategy, where the number of bed nets allocated per household is calculated on the basis of household composition and assumptions about who sleeps with whom. We set out to evaluate the performance of the novel allocation strategy. METHODS: A total of 1994 households were visited during household surveys following two universal coverage bed net distribution campaigns in Sofala and Nampula provinces in 2010-2013. Each sleeping space was observed for the presence of a bed net, and the sleeping patterns for each household were recorded. The observed coverage and efficiency were compared to a simulated coverage and efficiency had conventional allocation strategies been used. A composite indicator, the product of coverage and efficiency, was calculated. Observed sleeping patterns were compared with the sleeping pattern assumptions. RESULTS: In households reached by the campaign, 93% (95% CI: 93-94%) of sleeping spaces in Sofala and 84% (82-86%) in Nampula were covered by campaign bed nets. The achieved efficiency was high, with 92% (91-93%) of distributed bed nets in Sofala and 93% (91-95%) in Nampula covering a sleeping space. Using the composite indicator, the novel allocation strategy outperformed all conventional strategies in Sofala and was tied for best in Nampula. The sleeping pattern assumptions were completely satisfied in 66% of households in Sofala and 56% of households in Nampula. The most common violation of the sleeping pattern assumptions was that male children 3-10 years of age tended not to share sleeping spaces with female children 3-10 or 10-16 years of age. CONCLUSIONS: The sleeping pattern assumptions underlying the novel bed net allocation strategy are generally valid, and net allocation using these assumptions can achieve high coverage and compare favourably with conventional allocation strategies.


Delivery of Health Care/methods , Family Characteristics , Insecticide-Treated Bednets/statistics & numerical data , Insecticides , Malaria/prevention & control , Mosquito Control/methods , Sleep , Adolescent , Adult , Animals , Beds , Child , Child, Preschool , Female , Health Care Surveys , Humans , Infant , Male , Mozambique , Primary Prevention/methods
16.
Br J Cancer ; 113(1): 46-56, 2015 Jun 30.
Article En | MEDLINE | ID: mdl-26010414

BACKGROUND: Human sarcomas with a poor response to vascular endothelial growth factor-A (VEGF-A) inhibition and radiation therapy (RT) have upregulation of hypoxia-inducible factor 1α (HIF-1α) and HIF-1α target genes. This study examines the addition of the hypoxia-activated chemotherapy TH-302 to VEGF-A inhibition and RT (a.k.a. trimodality therapy). METHODS: Trimodality therapy was examined in two xenograft models and in vitro in tumour endothelial cells and sarcoma cell lines. RESULTS: In both mouse models, VEGF-A inhibition and radiation showed greater efficacy than either therapy alone in slowing sarcoma growth. When TH-302 was added, this trimodality therapy completely blocked tumour growth with tumours remaining dormant for over 3 months after cessation of therapy. Trimodality therapy caused 2.6- to 6.2-fold more endothelial cell-specific apoptosis than bimodality therapies, and microvessel density and HIF-1α activity were reduced to 11-13% and 13-20% of control, respectively. When trimodality therapy was examined in vitro, increases in DNA damage and apoptosis were much more pronounced in tumour endothelial cells compared with that in sarcoma cells, especially under hypoxia. CONCLUSIONS: The combination of TH-302, VEGF-A inhibition, and RT is highly effective in preclinical models of sarcoma and is associated with increased DNA damage and apoptosis in endothelial cells and decreased HIF-1α activity.


Antineoplastic Agents/therapeutic use , Hypoxia-Inducible Factor 1, alpha Subunit/physiology , Nitroimidazoles/therapeutic use , Phosphoramide Mustards/therapeutic use , Sarcoma/drug therapy , Sarcoma/radiotherapy , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Activation, Metabolic , Animals , Antineoplastic Agents/pharmacokinetics , Combined Modality Therapy , Humans , Male , Mice , Mice, Inbred BALB C , Nitroimidazoles/pharmacokinetics , Phosphoramide Mustards/pharmacokinetics , Xenograft Model Antitumor Assays
17.
Transbound Emerg Dis ; 62(3): 252-63, 2015 Jun.
Article En | MEDLINE | ID: mdl-23731597

The largest epidemic of foot-and-mouth disease (FMD) in Korea since the first record in 1911 occurred between November 2010 and April 2011. The outbreak was confirmed in 153 farms, and more than three million animals were destroyed. This study presents the temporal and spatial distribution patterns, epidemiological investigation and the control measures for the 2010/2011 epidemic in Korea. The index case of this 2010/2011 FMD epidemic was reported in a pig-farming complex with five piggeries in Andong, GyeongBuk Province, on 28 November 2010, and the outbreak lasted 145 days. The largest number of new detection of the infected farms per day was recorded in mid-January. Epidemiological investigation revealed that the FMD virus had spread from farm to farm through routine movements associated with animal husbandry operations. In contrast to FMD epidemics in other countries in which movement of the infected animals largely contributed to the spread of the disease, human behaviours were major factors in the spread of the FMD virus in the Korean epidemic. The 2010/2011 epidemic was first confirmed in a local small and medium city where share of smallholder producers is higher than that of other provinces. Although Korea had a well-developed emergent response system with the experience of controlling infection and re-obtaining FMD-free status after the previous epidemics, Korea was prompted to revise their contingency plan by tailoring it to its unique livestock environment. Practical contingency plans tailored to Korea for control of FMD can be fully effective when farmers, livestock-related agencies, veterinary service providers and the general public work together.


Disease Outbreaks/veterinary , Foot-and-Mouth Disease/epidemiology , Swine Diseases/epidemiology , Swine Diseases/virology , Agriculture , Animal Husbandry , Animals , Disease Outbreaks/prevention & control , Foot-and-Mouth Disease/prevention & control , Foot-and-Mouth Disease/transmission , Foot-and-Mouth Disease/virology , Foot-and-Mouth Disease Virus/classification , Humans , Livestock , Republic of Korea/epidemiology , Serogroup , Swine , Swine Diseases/prevention & control , Swine Diseases/transmission
18.
Bone Marrow Transplant ; 48(3): 425-32, 2013 Mar.
Article En | MEDLINE | ID: mdl-22941384

The aims of this study were to investigate the outcomes of second salvage auto-SCT and to identify the impacts of a second auto-SCT compared with systemic chemotherapy alone on disease outcome. Data from 48 patients who underwent second auto-SCT were matched to 144 patients (1:3) who received systemic chemotherapy alone from the Korean Myeloma Registry. Groups were matched for nine potential prognostic factors and compared for treatment outcomes. The median age of matching-pairs at relapse was 55.5 years. A total of 156 patients (81%) received vincristine, doxorubicin and dexamethasone induction therapy before the first auto-SCT. Thirty-five patients (73%) in the second auto-SCT group received novel agent-based therapies before the second auto-SCT, and similar proportion in both groups received novel therapies after relapse of front-line auto-SCT. With a median follow-up of 55.3 months, patients who underwent a second auto-SCT had significantly better median OS (55.5 vs 25.4 months, P=0.035). In multivariate analysis for OS, <18 months time to progression after first auto-SCT, International Staging System III and salvage chemotherapy alone were independent predictors for worse OS. The outcomes of second auto-SCT appear to be superior to those of systemic chemotherapy alone. A randomized trial comparing both treatment strategies is required.


Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Multiple Myeloma/drug therapy , Multiple Myeloma/surgery , Stem Cell Transplantation/methods , Adult , Aged , Combined Modality Therapy , Dexamethasone/administration & dosage , Disease-Free Survival , Doxorubicin/administration & dosage , Female , Humans , Male , Matched-Pair Analysis , Middle Aged , Salvage Therapy , Stem Cell Transplantation/adverse effects , Survival Rate , Treatment Outcome , Vincristine/administration & dosage
19.
Biosens Bioelectron ; 40(1): 258-64, 2013 Feb 15.
Article En | MEDLINE | ID: mdl-22883747

The gold nanowires array electrode (AuNWsA) was synthesized by two step electrodeposition, which provided well oriented vertically aligned nanowires. The dimensions of the nanowires were determined by scanning electron micrograph and found to be around 1.5 µm in length with 200 nm diameter. Each nanowire was separated by a distance of 2-3 times the diameter of the nanowire itself. The electrochemical performance of the AuNWsA electrode was evaluated using cyclic voltammetry (CV) and electrochemical impedance spectroscopy (EIS). Using these analytical tools, this AuNWsA electrode was shown to have a high effective surface area and excellent electron transfer surfaces compared with flat bare Au electrode. The AuNWsA electrode was then used as an electrochemical biosensor electrode by immobilizing probe DNA and analyzed by CV, EIS and Fourier transform infrared measurements. The results of this analysis suggested that the AuNWsA electrode provides good surfaces for the immobilization and hybridization of DNA. The selectivity of the probe DNA immobilized AuNWsA electrode was tested using non-complementary and one base pair mismatching DNA. The detection limit of the AuNWsA electrode was determined to be 6.78×10(-9) M, which is two times smaller than the bare Au electrode.


Biosensing Techniques/instrumentation , Conductometry/instrumentation , DNA/genetics , Electrodes , Nanotubes/chemistry , Sequence Analysis, DNA/instrumentation , Equipment Design , Equipment Failure Analysis , Reproducibility of Results , Sensitivity and Specificity
20.
Ann Oncol ; 24(3): 756-60, 2013 Mar.
Article En | MEDLINE | ID: mdl-23117072

BACKGROUND: This study explored the impact of genetic polymorphisms in cytochrome P450 (CYP) enzymes and transporters on the plasma trough concentration of imatinib mesylate (IM) and clinical response in chronic myeloid leukemia (CML). PATIENTS AND METHODS: In total, 82 patients with CML who had been administered 400 mg IM daily for over 6 months were genotyped for 11 single-nucleotide polymorphisms in nine genes (CYP3A4, CYP3A5, CYP2C9, CYP2C19, CYP2D6, ABCB1, SLC22A1, SLC22A2 and ABCG2) using blood samples. The trough imatinib concentration and clinical responses were assessed 6 months after the initiation of IM therapy. RESULTS: The CC, CA and AA genotypes in ABCG2 421C>A gave significantly different frequencies for the major molecular response (MMR) (P = 0.02). However, no significant differences were found between the genotypes of the CYP enzymes and transporters identified in this study and the imatinib plasma trough concentrations and clinical response frequencies, except for the correlation of ABCG2 with MMR. CONCLUSIONS: The results of the present study may indicate that the ABCG 421C>A genetic polymorphism influences the MMR of imatinib in patients with CML.


Antineoplastic Agents/pharmacokinetics , Benzamides/pharmacokinetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Piperazines/pharmacokinetics , Polymorphism, Single Nucleotide , Pyrimidines/pharmacokinetics , ATP Binding Cassette Transporter, Subfamily B , ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics , ATP Binding Cassette Transporter, Subfamily G, Member 2 , ATP-Binding Cassette Transporters/genetics , Adolescent , Adult , Aged , Aryl Hydrocarbon Hydroxylases/genetics , Female , Gene Frequency , Genotype , Humans , Imatinib Mesylate , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/enzymology , Male , Middle Aged , Neoplasm Proteins/genetics , Organic Cation Transport Proteins/genetics , Organic Cation Transporter 2 , Treatment Outcome , Young Adult
...